Roche's Mircera Banned From U.S. In Amgen's Win

Law360, New York (December 23, 2009, 2:40 PM EST) -- A federal judge has enjoined Swiss drugmaker Hoffmann-La Roche Inc. from selling its anemia drug Mircera in the U.S. until mid-2014 following a settlement Roche reached with Amgen Inc. admitting that its medication infringes five patents for Amgen's own anemia drugs.

Judge William G. Young of the U.S. District Court for the District of Massachusetts on Tuesday entered a final judgment and permanent injunction resolving the four-year battle, dismissing the case with prejudice based on the parties' stipulation that Roche's red blood cell booster infringes multiple...
To view the full article, register now.